Sangamo Therapeutics, Inc. (SGMO)
SGMO moved a median of -0.55% 30 minutes after news, and -2.17% by the close. How SGMO actually reacts to news — the realized, point-in-time move the market made, measured across 300 labeled events over the last three years with zero look-ahead.
SGMO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.66% | 38% | 297 |
| 30-min | -0.55% | 38% | 297 |
| 60-min | -0.84% | 39% | 297 |
| to close | -2.17% | 36% | 297 |
| Middle 50% of SGMO reactions | -2.54% to +1.42% |
|---|---|
| Median reaction (30-min) | -0.55% |
| Measured reactions | 300 |
Half of all Sangamo Therapeutics, Inc. news events land between -2.54% and +1.42% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SGMO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 14 | +0.71% | 64% | +1.09% |
| Coverage initiations | 21 | -0.76% | 33% | -2.27% |
| Rating reiterations | 54 | -0.03% | 46% | -0.57% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how SGMO ranks against every other measured name →
That’s how SGMO usually reacts — get an email when it moves on news →Email me when SGMO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SGMO's baseline. Nothing else.
Recent SGMO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | Press release | GlobeNewswire | — | — | |
| Form 8-K SANGAMO THERAPEUTICS, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K SANGAMO THERAPEUTICS, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +4.68% | -3.77% | |
| Form 8-K/A SANGAMO THERAPEUTICS, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas | Press release | GlobeNewswire | +4.68% | -3.77% | |
| Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders | Press release | GlobeNewswire | -1.06% | -8.99% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +3.85% | |
| Form 8-K SANGAMO THERAPEUTICS, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.85% | |
| Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.00% | +3.85% | |
| Sangamo Therapeutics Announces First Quarter 2026 Earnings Call | Press release | GlobeNewswire | +2.92% | +10.62% | |
| Form 10-K/A SANGAMO THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.17% | -6.88% | |
| Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) | Press release | GlobeNewswire | -1.17% | -6.88% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +4.02% | +8.85% | |
| Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market | Press release | GlobeNewswire | +4.02% | +8.85% | |
| Form 10-K SANGAMO THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.44% | +7.35% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | +7.35% | |
| Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results | Press release | GlobeNewswire | -1.44% | +7.35% | |
| Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call | Press release | GlobeNewswire | -0.20% | -5.09% | |
| Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | Press release | GlobeNewswire | -0.53% | +7.95% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | -4.09% | -13.35% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | +1.34% | -14.08% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | -4.09% | -13.35% | |
| Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering | Press release | GlobeNewswire | +1.34% | -14.08% | |
| Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 | Press release | GlobeNewswire | -4.09% | -13.35% | |
| Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | Press release | GlobeNewswire | +3.57% | -1.71% | |
| Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | Press release | GlobeNewswire | -5.80% | -7.52% | |
| Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease | Press release | GlobeNewswire | -13.82% | -20.41% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +11.93% | +9.64% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +11.93% | +9.64% | |
| Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +11.93% | +9.64% | |
| Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call | Press release | GlobeNewswire | +0.93% | +3.00% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Oct 29 | SEC filing · Form 8-K | SEC EDGAR | +0.57% | +0.17% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +1.38% | +1.28% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | -4.74% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | -3.72% | +2.12% | |
| Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 | Press release | GlobeNewswire | -3.72% | +2.12% | |
| Form S-8 SANGAMO THERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | +0.45% | -4.92% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.31% | +1.53% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -5.31% | +1.53% | |
| Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results | Press release | GlobeNewswire | -5.31% | +1.53% | |
| Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call | Press release | GlobeNewswire | -3.34% | +4.10% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +2.79% | +13.57% | |
| Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | Press release | Business Wire | +2.79% | +13.57% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -1.72% | -3.38% | |
| Form 8-K SANGAMO THERAPEUTICS, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -2.70% | -11.80% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -6.33% | -2.95% | |
| Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Press release | Business Wire | -6.33% | -2.95% | |
| Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day | Press release | Business Wire | -6.33% | -2.95% | |
| Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results | Press release | Business Wire | -6.33% | -2.95% | |
| Form 8-K SANGAMO THERAPEUTICS, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -2.51% | +3.44% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SGMO section they belong to.
Where else SGMO is measured.
SGMO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EIDOS THERAPEUTICS (EIDX) | 300 | +0.01% | 51% |
| Grifols, S.A. - American Depositary Shares (GRFS) | 300 | -0.13% | 39% |
| Merit Medical Systems, Inc. (MMSI) | 299 | -0.03% | 48% |
| PLx Pharma Inc. (PLXP) | 299 | -0.05% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Sangamo Therapeutics, Inc.'s median reaction calculated?
Every labeled SGMO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 300 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 38% of SGMO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SGMO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.